Cancer immunotherapy: T cells get a ride

Nature Reviews Drug Discovery 16, 383 (2017). doi:10.1038/nrd.2017.103 Author: M. Teresa Villanueva Strategies that inhibit the immune checkpoint blockade (ICB) and reactivate T cells using monoclonal antibodies against programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1) have been used to successfully treat immunogenic tumours, and recent efforts have focused on combining this approach with
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: Research Highlight Source Type: research